DK1556029T3 - Thiomolybdatsalte og anvendelser deraf - Google Patents

Thiomolybdatsalte og anvendelser deraf Download PDF

Info

Publication number
DK1556029T3
DK1556029T3 DK03765973.7T DK03765973T DK1556029T3 DK 1556029 T3 DK1556029 T3 DK 1556029T3 DK 03765973 T DK03765973 T DK 03765973T DK 1556029 T3 DK1556029 T3 DK 1556029T3
Authority
DK
Denmark
Prior art keywords
tetrathiomolybdate
bis
compound
compounds
cancer
Prior art date
Application number
DK03765973.7T
Other languages
English (en)
Inventor
Robert J Ternansky
Andrew Mazar
Patricia L Gladstone
Dimitri Coucouvanis
Amy L Allan
Sean M O'hare
Mellissa L P Price
Steven Robert Pirie-Shepherd
Fernando Donate
Original Assignee
Wilson Therapeutics Ab
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/202,346 external-priority patent/US20040019043A1/en
Application filed by Wilson Therapeutics Ab, Univ Michigan filed Critical Wilson Therapeutics Ab
Application granted granted Critical
Publication of DK1556029T3 publication Critical patent/DK1556029T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
    • C07D213/20—Quaternary compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F11/00—Compounds containing elements of Groups 6 or 16 of the Periodic System
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/62—Quaternary ammonium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/62—Quaternary ammonium compounds
    • C07C211/63—Quaternary ammonium compounds having quaternised nitrogen atoms bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/62—Quaternary ammonium compounds
    • C07C211/64—Quaternary ammonium compounds having quaternised nitrogen atoms bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/06—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/60—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/037—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements with quaternary ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Claims (12)

1. Thiomolybdatforbindelse, eller et solvat eller hydrat deraf valgt fra gruppen bestående af propan-l,3-bis (trimethylamnnoniunn)tetrathionnolybdat; bis(l-ethyl-3-methyl-l/7-imidazolium)tetrathionnolybdat; bis(trinnethylphenylannnnoniunn)tetrathiomolybdat; bis(tetrapropylammoniunn)tetrathionnolybdat; bis(cholin)tetrathiomolybdat; bis(triethylphenylannnnonium)tetrathiomolybdat; bis(methyltriethylammonium)tetrathiomolybdat; bis(l,l-dimethylpyrrolidinium)-tetrathiomolybdat; bis(trimethylbenzylammonium)tetrathiomolybdat; pentan-l,5-bis (trimethylammonium)tetrathiomolybdat; bis(vinyltrimethylammonium)tetrathiomolybdat; bis(cyclopropylmethyltrimethylammonium)tetrathiomolybdat; hexan-l,6-bis(trimethyl-ammonium)tetrathiomolybdat; bis(acetylcholin)tetrathiomolybdat; bis(l,4-dimethylpyridinium)tetrathiomolybdat; ethylenbis(trimethylammonium)tetra-thiomolybdat; butan-l,4-bis(trimethylammonium)tetrathiomolybdat.
2. Thiomolybdatforbindelse, eller et solvat eller hydrat deraf, ifølge krav 1, der har øget stabilitet under atmosfæriske betingelser som sammenlignet med bis(ammonium)tetrathiomolybdat, valgt fra gruppen bestående af propan-1, 3-bis (trimethylammonium)tetrathiomolybdat; bis(l-ethyl-3-methyl-lH-imidazolium)tetrathio-molybdat; bis(trimethylphenylammonium)tetrathiomolybdat; bis(tetrapropylammonium)tetrathiomolybdat; bis(cholin)tetrathiomolybdat; bis(triethylphenylammonium)tetrathiomolybdat; bis(methyltriethylammonium)tetrathiomolybdat; bis(l,l-dimethylpyrrolidinium)tetra-thiomolybdat; bis(trimethylbenzylammonium)tetrathiomolybdat; pentan-l,5-bis (trimethylammonium)tetrathiomolybdat; bis(vinyltrimethylammonium)tetrathiomolybdat; bis(cyclopropylmethyltrimethylammonium)tetrathiomolybdat; hexan-l,6-bis (trimethylammonium)tetrathiomolybdat.
3. Tetrathiomolybdatforbindelsen ifølge krav 1 eller 2, til anvendelse som et medikament.
4. Tetrathiomolybdatforbindelsen ifølge krav 1 eller 2, til anvendelse i en fremgangsmåde til behandling af en sygdom eller tilstand valgt fra gruppen bestående af cancer, våd macula degeneration, rheumatoid arthritis, afvigende vaskularisering, forhøjede kobberniveauer, kobbermetabolismeforstyrrelser, og fedme.
5. Tetrathiomolybdatforbindelsen ifølge krav 4, til anvendelse i en fremgangsmåde til behandling af en cancer valgt fra gruppen bestående af brystcancer, nyrecancer, hjernecancer, tarmcancer, prostatacancer, chondrosarcom, angiosarcom, og lungecarcinom.
6. Tetrathiomolybdatforbindelsen ifølge krav 4, til anvendelse i en fremgangsmåde til behandling af en neurodegerativ sygdom valgt fra gruppen bestående af Alzheimer's sygdom, amyotrof lateral sklerose, og prionsygdom.
7. Tetrathiomolybdatforbindelsen ifølge krav 1 eller 2, til anvendelse i en fremgangsmåde til behandling af Wilson's sygdom.
8. Tetrathiomolybdatforbindelsen ifølge krav 1 eller 2, til anvendelse som et medikament i kombination med mindst et andet terapeutisk middel.
9. Tetrathiomolybdatforbindelsen ifølge krav 8, hvor det andet terapeutiske middel er valgt fra kemoterapeutiske midler, antimetabolitter, purinanaloger, naturprodukter, platinkoordineringskomplekser, mitoxantron, hydroxyu ri nstof, procarbazin, hormoner, antagonister, anti-angiogenesemidler, anti-angiogeneseinhibitorer, apoptose-inducerende midler og anti-fedmemidler.
10. Tetrathiomolybdatforbindelsen ifølge et hvilket som helst af kravene 1-9, hvor tetrathiomolybdatforbindelsen er bis(cholin)tetrathiomolybdat.
11. Bis(cholin)tetrathiomolybdat til anvendelse i en fremgangsmåde til behandling af Wilson's sygdom.
12. Thiomolybdatforbindelse valgt fra gruppen bestående af tetrathiomolybdatforbindelser ifølge krav 1 eller 2 til anvendelse i en fremgangsmåde til behandling af det humane eller dyriske legeme, hvor forbindelsen administreres én eller to gange pr. dag ved oral forsinket frigivelses-administration.
DK03765973.7T 2002-07-23 2003-07-22 Thiomolybdatsalte og anvendelser deraf DK1556029T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/202,346 US20040019043A1 (en) 2002-07-23 2002-07-23 Thiomolybdate analogues and uses thereof
US43474202P 2002-12-18 2002-12-18
US43695803A 2003-05-12 2003-05-12
US10/447,585 US7189865B2 (en) 2002-07-23 2003-05-28 Thiomolybdate analogues and uses thereof
PCT/US2003/023031 WO2004009034A2 (en) 2002-07-23 2003-07-22 Thiomolybdate analogues and uses thereof

Publications (1)

Publication Number Publication Date
DK1556029T3 true DK1556029T3 (da) 2014-03-10

Family

ID=30773643

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03765973.7T DK1556029T3 (da) 2002-07-23 2003-07-22 Thiomolybdatsalte og anvendelser deraf

Country Status (19)

Country Link
US (1) US7189865B2 (da)
EP (1) EP1556029B1 (da)
JP (1) JP2006506466A (da)
KR (1) KR20050053596A (da)
CN (1) CN100531732C (da)
AU (1) AU2003256704A1 (da)
BR (1) BR0312851A (da)
CA (1) CA2493127A1 (da)
DK (1) DK1556029T3 (da)
EA (1) EA200500250A1 (da)
ES (1) ES2448800T3 (da)
HR (1) HRP20050174A2 (da)
IL (1) IL166448A0 (da)
MX (1) MXPA05000870A (da)
NO (1) NO20050917L (da)
PL (1) PL374821A1 (da)
PT (1) PT1556029E (da)
SI (1) SI1556029T1 (da)
WO (1) WO2004009034A2 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1115389B1 (en) * 1998-09-25 2014-03-12 PhilERA New Zealand Limited Fructosamine oxidase: antagonists and inhibitors
AU4678300A (en) * 1999-04-30 2000-11-17 Slil Biomedical Corporation Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
WO2002038105A2 (en) * 2000-11-08 2002-05-16 Slil Biomedical Corporation Novel polyamine analog-amino acid conjugates useful as anticancer agents
EP1177197B1 (en) * 1999-04-30 2006-08-09 Cellgate, Inc. Polyamines and their use in therapy
CA2458622A1 (en) * 2001-08-24 2003-03-06 Maine Medical Center Research Institute Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto
AU2002340224B2 (en) * 2001-10-16 2008-11-27 Progen Pharmaceuticals, Inc Oligoamine compounds and derivatives thereof for cancer therapy
WO2003077901A1 (en) * 2002-03-08 2003-09-25 Protemix Corporation Limited Preventing and/or treating cardiovascular disease and/or associated heart failure
EP1531827A4 (en) * 2002-05-24 2009-07-08 Univ Michigan COPPER-REDUCING TREATMENT FOR INFLAMMATORY AND FIBROTIC DISEASES
JP2005538093A (ja) 2002-07-23 2005-12-15 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン 抗血管形成療法のための、テトラポリアンモニウムテトラチオモリブデートおよび関連化合物
WO2004017956A1 (en) * 2002-08-20 2004-03-04 Protemix Corporation Limited Dosage forms and related therapies
BRPI0410651A (pt) * 2003-05-27 2006-07-04 Attenuon Llc composto, composição farmacêutica, e, métodos para tratar ou prevenir cáncer, degeneração macular do tipo úmida ou artrite reumatóide, vascularização aberrante, nìveis de cobre em excesso, obesidade e doença neurodegenerativa em um paciente
EP1729784A1 (en) * 2004-02-23 2006-12-13 Attenuon, LLC Formulations of thiomolybdate or thiotungstate compounds and uses thereof
EP1721010A2 (en) * 2004-02-24 2006-11-15 Attenuon, LLC Inhibition of superoxide dismutase by tetrathiomolybdate: identification of new anti-angiogenic and antitumor agents
DK1778618T3 (da) 2004-07-19 2014-03-10 Philera New Zealand Ltd Syntese af triethylentetraminer
JP5099620B2 (ja) * 2006-10-26 2012-12-19 学校法人日本大学 筋萎縮性側索硬化症治療薬
US7893289B2 (en) * 2007-02-21 2011-02-22 Ssv Therapeutics, Inc. Adamantanamines and neramexane salts of thiomolybdic and thiotungstic acids
PL381862A1 (pl) 2007-02-28 2008-09-01 Trigendo Spółka Z Ograniczoną Odpowiedzialnością Zastosowanie związków pirydyniowych i sposób leczenia
US20090028800A1 (en) * 2007-07-27 2009-01-29 Peeples William H Method of Treating Postpartum Depression and Aggression
WO2009123569A1 (en) * 2008-03-31 2009-10-08 Agency For Science, Technology And Research Method for treating neurological disorders with imidazolium and imidazolinium compounds
JP6285164B2 (ja) * 2013-12-05 2018-02-28 デクセリアルズ株式会社 化合物、熱硬化性樹脂組成物、及び熱硬化性シート
CA3010127C (en) * 2016-02-23 2022-10-04 Vanderbilt Chemicals, Llc Quaternary ammonium sulfur-containing binuclear molybdate salts as lubricant additives
US11419832B2 (en) * 2017-12-04 2022-08-23 Alexion Pharmaceuticals, Inc. Bis-choline tetrathiomolybdate for treating Wilson Disease
ES2912306T3 (es) * 2017-12-04 2022-05-25 Alexion Pharma Inc Tetratiomolibdato de bis-colina para el tratamiento de enfermedad de Wilson
JP2021512948A (ja) * 2018-02-06 2021-05-20 アレクシオン・ファーマ・インターナショナル・オペレーションズ・アンリミテッド・カンパニー ビス−コリンテトラチオモリブデン酸塩の結晶性粒子
WO2019158719A1 (en) 2018-02-15 2019-08-22 Wilson Therapeutics Ab Process for preparation of bis-choline tetrathiomolybdate
US20220081387A1 (en) 2019-01-14 2022-03-17 Alexion Pharmaceuticals, Inc. Methods for preparing ammonium tetrathiomolybdate
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
JP2023549037A (ja) 2020-10-07 2023-11-22 シーティーアイ バスキュラー アーゲー 生物活性型に変換可能なデバイスおよび関連する方法
WO2022165339A1 (en) * 2021-01-31 2022-08-04 Alexion Pharmaceuticals, Inc. Novel formulation for treating copper metabolism-associated diseases or disorders
WO2023086873A1 (en) * 2021-11-10 2023-05-19 Reverspah Llc Methods and compositions for treating cancer
CN114042083B (zh) * 2021-12-06 2022-08-30 湖南师范大学 四硫代钼酸盐的增肌及治疗应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909541A (en) * 1955-01-07 1959-10-20 Inst Francais Du Petrole Nitrogenous thiomolybdates
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4400282A (en) 1980-12-05 1983-08-23 Gulf Research & Development Company Lubricating oils containing quaternary ammonium thiomolybdates
US4343746A (en) * 1980-12-10 1982-08-10 Gulf Research & Development Company Quaternary ammonium thiomolybdates
US4430443A (en) * 1982-07-20 1984-02-07 Exxon Research And Engineering Co. Supported carbon-containing molybdenum and tungsten sulfide catalysts, their preparation and use
GB8504253D0 (en) * 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
DE3815221C2 (de) * 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5698155A (en) * 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
DK0814860T3 (da) * 1995-03-14 2000-05-08 Siemens Ag Ultrasonisk forstøveranordning med aftagelig præcisionsdoseringsendhed
DK0814861T3 (da) * 1995-03-14 2002-10-07 Siemens Ag Udskiftelig præcisionsdoseringsenhed til ultralydforstøveranordning
DE69833030T2 (de) 1997-10-17 2006-08-24 Ebara Corp. Verfahren und vorrichtung zur behandlung von abgasen aus der halbleiterherstellung
NZ504021A (en) * 1997-10-17 2003-04-29 Systemic Pulmonary Delivery Lt Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
WO2000013712A2 (en) * 1998-09-04 2000-03-16 The Regents Of The University Of Michigan Methods and compositions for the prevention or treatment of cancer
CN1262226A (zh) 1999-12-03 2000-08-09 中国科学院兰州化学物理研究所 硫代钼酸盐及其制备方法和用途
EP1531827A4 (en) * 2002-05-24 2009-07-08 Univ Michigan COPPER-REDUCING TREATMENT FOR INFLAMMATORY AND FIBROTIC DISEASES
JP2005538093A (ja) * 2002-07-23 2005-12-15 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン 抗血管形成療法のための、テトラポリアンモニウムテトラチオモリブデートおよび関連化合物

Also Published As

Publication number Publication date
EA200500250A1 (ru) 2005-12-29
US7189865B2 (en) 2007-03-13
PL374821A1 (en) 2005-10-31
EP1556029A4 (en) 2008-06-25
MXPA05000870A (es) 2005-08-29
IL166448A0 (en) 2006-01-15
SI1556029T1 (sl) 2014-06-30
JP2006506466A (ja) 2006-02-23
NO20050917L (no) 2005-04-20
CN100531732C (zh) 2009-08-26
US20040019087A1 (en) 2004-01-29
KR20050053596A (ko) 2005-06-08
WO2004009034A3 (en) 2004-09-10
HRP20050174A2 (en) 2005-10-31
ES2448800T3 (es) 2014-03-17
EP1556029A2 (en) 2005-07-27
EP1556029B1 (en) 2013-11-27
CA2493127A1 (en) 2004-01-29
CN1684678A (zh) 2005-10-19
BR0312851A (pt) 2005-07-12
WO2004009034A2 (en) 2004-01-29
PT1556029E (pt) 2014-03-04
AU2003256704A1 (en) 2004-02-09

Similar Documents

Publication Publication Date Title
DK1556029T3 (da) Thiomolybdatsalte og anvendelser deraf
US20110151022A1 (en) Thiotungstate analogues and uses thereof
US20060148891A1 (en) Formulations of thiomolybdate or thiotungstate compounds and uses thereof
AU6571200A (en) Sulfonyl carboxamide derivatives, method for their production and their use as medicaments
JP2018517672A (ja) イソオキサゾリル置換イミダゾピリジン類
US7902394B2 (en) Calcilytic compounds
US20040019043A1 (en) Thiomolybdate analogues and uses thereof
EP3353163B1 (en) 2,3,4,5-tetrahydropyridin-6-amine derivatives
CN101389617A (zh) 制备哌嗪基和二氮杂环庚烷基苯甲酰胺衍生物的新方法
EP1664013B1 (en) Calcilytic compounds
WO2007142626A1 (en) Methods and compositions for increasing bioavailability of thiomolybdate and thiotungstate compounds
AU2006210627B2 (en) Acid addition salts of Ac-PHSCN-NH2
EP4286385A1 (en) Novel maleate of triazolopyrazine derivative, composition, use method, and preparation method therefor
CN106810532A (zh) 一类胺烷氧基噻吨酮类化合物、其制备方法和用途
CN114478318A (zh) 二腈异佛尔酮衍生物、其制备方法及应用
TW200538107A (en) Thiotungstate analogues and uses thereof
CZ220392A3 (en) Substituted 1-phenyl-1-benzoylamino-5-aminopentanes, their preparation and use